Immunohistochemical markers to differentiate primary adenocarcinoma and squamous cell carcinoma of the lung: diagnostic test accuracy meta-analysis

Not Applicable

• Conditions: SCLC

• Registration Number: JPRN-UMIN000041664
• Lead Sponsor: Yokohama City University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-03
• Study Completion: 2021-09-03
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

An article that provide data of either sensitivity or specificity will be excluded since bivariate analysis is not applicable to such data. Specificity evaluated among lung cancer cases will not be used for our analysis because analysis including both NSCLC and small-cell lung cancer will underestimate the specificity of markers. Studies focusing on non-pulmonary cancers and metastatic lung cancer of non-pulmonary origin will be excluded. Similarly, studies that compared NSCLC subtypes and mesothelioma will not be accepted.

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sensitivity, specificity, area under curve (AUC), and diagnostic odds ratio will be evaluated. If two or more of cutoffs are applied in an original article, all of weak, moderate, and strong positive will be collectively considered positive. To diagnose adenocarcinoma, both adenocarcinoma and adenosquamous carcinoma will be counted since adenosquamous carcinoma has adenocarcinoma component while large cell carcinoma and NSCLC not otherwise specified will not be counted as adenocarcinoma. Similar algorithm will be applied to diagnose squamous cell carcinoma. If data for multiple clones, e.g. 8G7G3/1, SPT24, and SP141 clones of TTF-1, are available, the data of 8G7G3/1 will be selected for our analysis because 8G7G3/1 clone has been known to provide the best diagnostic odds ratio among the three clones. Subgroup analysis focusing on each clone will be also done.